After speaking with "with a highly experienced Washington-based medical device reimbursement consultant," Stifel quotes the consultant as saying that CMS' decision on Boston Scientific's Watchman device "was generally positive." However, he added that CMS must clarify its phrase "contraindication to warfarin" and what it means by contraindication, as well as the design of the national registry trial it's requiring. According to Stifel, the consultant "seemed to suggest" that these issues could be resolved by talks between the company and the agency. Stifel keeps a $22 price target and Buy rating on Boston Scientific.